公开(公告)号：US06448255B1

公开(公告)日：2002-09-10

申请号：US09965957

申请日：2001-09-28

Applicant: Hassan M. Elokdah ,  Theodore S. Sulkowski ,  Sie-Yearl Chai ,  John Babiak

Inventor： Hassan M. Elokdah ,  Theodore S. Sulkowski ,  Sie-Yearl Chai ,  John Babiak

IPC: C07D48704

CPC classification number: A61K41/0057

Abstract: Antiatherosclerotic compounds are provided which have the following structure: wherein: R is hydrogen, lower alkyl, alkenyl, alkynyl, aryl, heteroaryl, or aryl or heteroaryl substituted with one or more members of the group consisting of alkyl, hydroxy, alkoxy, perfluoroalkyl, perfluoroalkoxy, alkylthio, nitro, amino, mono or di-alkylamino, and halogen; D is C—H, carbon bound to R5 or nitrogen; R1, R2, R3, and R4 are each independently hydrogen, alkyl, or taken together form a ring; R5 is one or more groups selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxy, alkoxy, perfluoroalkyl, perfluoroalkoxy, alkylthio, nitro, amino, mono or di-alkylamino, or halogen; n is an integer of 0-3; or pharmaceutically acceptable salts thereof.

Abstract translation: 提供具有以下结构的抗动脉粥样硬化化合物：其中：R是氢，低级烷基，烯基，炔基，芳基，杂芳基或被一个或多个由烷基，羟基，烷氧基，全氟烷基， 全氟烷氧基，烷硫基，硝基，氨基，一或二烷基氨基和卤素; D是CH，与R5或氮键合的碳原子; R1，R2，R3和R4各自独立地为氢，烷基或一起形成环; R5是选自氢，烷基，烯基，炔基，芳基，羟基，烷氧基，全氟烷基，全氟烷氧基，烷硫基，硝基，氨基，单或二烷基氨基或卤素中的一个或多个基团; n是0-3的整数; 或其药学上可接受的盐。

公开(公告)号：US5939435A

公开(公告)日：1999-08-17

申请号：US15178

申请日：1998-01-29

Applicant: John Babiak ,  Hassan Mahmoud Elokdah ,  Christopher Paul Miller ,  Theodore Sylvester Sulkowski

Inventor： John Babiak ,  Hassan Mahmoud Elokdah ,  Christopher Paul Miller ,  Theodore Sylvester Sulkowski

IPC: C07D215/48 ,  A61K31/47 ,  C07D215/14

CPC classification number: C07D215/48

Abstract: This invention relates to the use of 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase high density lipoprotein cholesterol (HDL-C) concentration and as therapeutic compositions for treating atherosclerotic conditions such as dyslipoproteinamias and coronary heart disease.

Abstract translation: 本发明涉及2-取代-1-酰基-1,2-二氢喹啉衍生物用于增加高密度脂蛋白胆固醇（HDL-C）浓度和作为用于治疗动脉粥样硬化病症如脂蛋白血症和冠心病的治疗组合物的用途。